Chemometec

ChemoMetec reported an adjusted loss of -$1.15 per share in the fourth quarter (expectation -$0.80), while revenue of $124m was slightly above forecasts. For fiscal 2025/2026 the company posted record revenue of DKK 511m, an EBITDA margin of 55.0% and XcytoMatic growth of 146%. Management raised the outlook for 2026/2027 but remained cautious; investors focused on the earnings miss, sending the stock down about 6.2%. ChemoMetec plans higher investments in software, automation and protocol development and expects XcytoMatic to become the main growth driver going forward. » Más en de.investing.com

ChemoMetec reported revenue of DKK 125m for the first quarter of 2025 (forecast DKK 124m) and earnings per share of 3.98. Revenue rose 8% in DKK (11% at constant exchange rates) and EBITDA was DKK 68.8m with a margin of 55%. Despite the positive figures, the stock fell about 4% to DKK 684. The company plans a phased rollout of the XM platform (soft launch 2026) and is strategically shifting toward software-based solutions. » Más en de.investing.com

ChemoMetec reported Q4 EPS of -$1.04 (expectation -$0.62) and revenue of $120m versus expected $128m. Restructuring costs weighed on results (total $12m, of which $8m in Q4). The stock nevertheless climbed 12.45% to $542 after management presented an optimistic outlook of 10–14% revenue growth, planned investments of $100m and new products (including Excitomatic XM40, XM50). Risks remain tariffs, currency fluctuations, intense competition and ongoing restructuring costs. » Más en de.investing.com